{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T19:26:47Z","timestamp":1789586807524,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The aim of this study was to evaluate the variation of dry eye disease (DED) prevalence in patients with atopic dermatitis (AD) treated with dupilumab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This prospective case\u2013control study included consecutive patients with moderate-to-severe AD scheduled for dupilumab between May and December 2021 and healthy subjects. DED prevalence, the Ocular Surface Disease Index, tear film breakup time test, osmolarity, Oxford staining score, and Schirmer test results were collected at baseline, 1 month, and 6 months after dupilumab therapy. The Eczema Area and Severity Index was assessed at baseline. Ocular side effects and discontinuation of dupilumab were also recorded.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Seventy-two eyes from 36 patients with AD treated with dupilumab and 36 healthy controls were included. Prevalence of DED increased from 16.7% at baseline to 33.3% at 6 months in the dupilumab group (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001), whereas it remained unchanged in the control group (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.110). At 6 months, the Ocular Surface Disease Index and Oxford score increased (from 8.5 \u00b1 9.8 to 11.0 \u00b1 13.0, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.068, and from 0.1 \u00b1 0.5 to 0.3 \u00b1 0.6, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.050, respectively), the tear film breakup time test and Schirmer test results decreased (from 7.8 \u00b1 2.6 s to 7.1 \u00b1 2.7 s, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001, and from 15.4 \u00b1 9.6 mm to 13.2 \u00b1 7.9 mm, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.036, respectively) in the dupilumab group, whereas they remained stable in the control group (<jats:italic toggle=\"yes\">P<\/jats:italic> &gt; 0.05). Osmolarity was unchanged (dupilumab <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.987 and controls <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.073). At 6 months after dupilumab therapy, 42% of patients had conjunctivitis, 36% blepharitis, and 2.8% keratitis. No severe side effects were reported, and none of the patients discontinued dupilumab. No association between Eczema Area and Severity Index and DED prevalence was shown.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>DED prevalence increased in patients with AD treated with dupilumab at 6 months. However, no severe ocular side effects were found and no patient discontinued therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000003341","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T09:00:35Z","timestamp":1688547635000},"page":"221-227","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Ocular Surface Disease in Patients With Atopic Dermatitis Treated With Dupilumab: A Prospective Case\u2013Control Study"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8881-0926","authenticated-orcid":false,"given":"Paola","family":"Marolo","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ribero","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caselgrandi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ghilardi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"de Sanctis","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Parisi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Fallico","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Catania, Catania, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ortoncelli","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Gelato","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mastorino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tibaldi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Roccuzzo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Quaglino","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Turin, Turin, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"issue":"suppl 1","key":"R1-20250723","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000370220","article-title":"Atopic dermatitis: global epidemiology and risk factors","volume":"66","author":"Nutten","year":"2015","journal-title":"Ann Nutr Metab"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0161-6420(90)32477-6","article-title":"Atopic keratoconjunctivitis","volume":"97","author":"Foster","year":"1990","journal-title":"Ophthalmology"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jaad.2020.08.127","article-title":"Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry","volume":"84","author":"Ari\u00ebns","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jdv.17981","article-title":"Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review","volume":"36","author":"Neagu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtos.2020.05.008","article-title":"Ocular surface disease associated with dupilumab treatment for atopic diseases","volume":"19","author":"Utine","year":"2021","journal-title":"Ocul Surf"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the ocular surface disease index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.ico.0000214802.40313.fa","article-title":"Dysfunctional tear syndrome: a Delphi approach to treatment recommendations","volume":"25","author":"Behrens","year":"2006","journal-title":"Cornea"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"6125","DOI":"10.1167\/iovs.10-5390","article-title":"An objective approach to dry eye disease severity","volume":"51","author":"Sullivan","year":"2010","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"R11-20250723","first-page":"775","article-title":"New international consensus statement about the definition, classification, ethiology, diagnostics and therapy of dry eye (TFOS DEWS II)","volume":"159","author":"Andr\u00e1s","year":"2018","journal-title":"Orv Hetil"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1038\/s41433-020-01379-9","article-title":"Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae","volume":"35","author":"Popiela","year":"2021","journal-title":"Eye (Lond)"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/ICO.0000000000002461","article-title":"Dupilumab-associated ocular surface disease: clinical characteristics, treatment, and follow-up","volume":"40","author":"Bohner","year":"2021","journal-title":"Cornea"},{"key":"R15-20250723","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1111\/jdv.15914","article-title":"Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis","volume":"34","author":"Voorberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/bjd.17538","article-title":"Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis","volume":"180","author":"Bakker","year":"2019","journal-title":"Br J Dermatol"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"},{"key":"R19-20250723","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"key":"R20-20250723","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajo.2019.01.026","article-title":"Estimated prevalence and incidence of dry eye disease based on coding analysis of a large, all-age United States Health Care System","volume":"202","author":"Dana","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R21-20250723","doi-asserted-by":"crossref","first-page":"DES64","DOI":"10.1167\/iovs.17-23746","article-title":"Short tear film breakup time-type dry eye","volume":"59","author":"Tsubota","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R22-20250723","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R23-20250723","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet (London, England)"},{"key":"R24-20250723","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R25-20250723","first-page":"411","article-title":"Use of subjective global assessment, patient-generated subjective global assessment and nutritional risk screening 2002 to evaluate the nutritional status of non-critically ill patients on parenteral nutrition","volume":"29","author":"Badia-Tahull","year":"2014","journal-title":"Nutr Hosp"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:03:11Z","timestamp":1753279391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000003341","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"2023-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}